Stocks
Bio-Techne Refiles Intent to Merge with Merck Amid FTC Review
Bio-Techne has refiled its intent to merge with Merck in an $11.3 billion deal, giving the Federal Trade Commission more time to review the agreement for competition concerns.
The life science tool company made this decision after initially filing its intention to merge with the pharmaceutical giant, prompting the FTC to scrutinize the deal for potential issues.
This move comes as a way for Bio-Techne to provide additional time for the FTC to review the proposed merger and address any concerns it may have regarding competition in the market.